Search research articles
Contact Us
Filters
Showing results (291-300 of 365) with videos related to
Page
of 37
Sort By:
The Journal of Biological Chemistry
|
July 2, 2013
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors
Swarna Mehrotra, Bhumika Sharma, Sonali Joshi, et al.
Blood
|
August 5, 2022
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.
The Journal of Biological Chemistry
|
October 18, 2012
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses
Bhumika Sharma, Sonali Joshi, Antonella Sassano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia
Gail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Investigational New Drugs
|
April 16, 2011
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
H M Kantarjian, S Padmanabhan, W Stock, et al.
Leukemia
|
March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
Courtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
American Journal of Hematology
|
June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study
Courtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
Cancers
|
May 14, 2022
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area
Alain Mina, Carlos Galvez, Reem Karmali, et al.
Leukemia
|
June 11, 2013
AKT is a therapeutic target in myeloproliferative neoplasms
I Khan, Z Huang, Q Wen, et al.
Page
of 37
Search research articles
Search
Showing results (291-300 of 365) with videos related to
Sort By:
Page
of 37
The Journal of Biological Chemistry
|
July 2, 2013
Essential role for the Mnk pathway in the inhibitory effects of type I interferons on myeloproliferative neoplasm (MPN) precursors
Swarna Mehrotra, Bhumika Sharma, Sonali Joshi, et al.
Blood
|
August 5, 2022
Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy
Shivani Handa, Jeong-Ok Lee, Andriy Derkach, et al.
The Journal of Biological Chemistry
|
October 18, 2012
Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses
Bhumika Sharma, Sonali Joshi, Antonella Sassano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 21, 2014
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia
Gail J Roboz, Todd Rosenblat, Martha Arellano, et al.
Investigational New Drugs
|
April 16, 2011
Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia
H M Kantarjian, S Padmanabhan, W Stock, et al.
Leukemia
|
March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplant
Courtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
American Journal of Hematology
|
June 24, 2023
Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study
Courtney D DiNardo, Stéphane De Botton, Daniel A Pollyea, et al.
British Journal of Haematology
|
February 18, 2014
Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy
Steven E Coutre, Megan Othus, Bayard Powell, et al.
Cancers
|
May 14, 2022
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area
Alain Mina, Carlos Galvez, Reem Karmali, et al.
Leukemia
|
June 11, 2013
AKT is a therapeutic target in myeloproliferative neoplasms
I Khan, Z Huang, Q Wen, et al.
Page
of 37